Skip to main content

Table 2 Efficacy and Safety Outcome

From: Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre

VariablesEnoxaparin
80 (53.3%)
Rivaroxaban 70 (46.7%)p-value
Primary Efficacy Outcomes
VTE Recurrence  0.42
 No72 (90.0%)60 (85.7%) 
 Yes8 (10.0%)10 (14.3%) 
• DVT recurrence  0.11
 Proximal3 (100.0%)6 (100.0%) 
 Distal0 (0.0%)0 (0.0%) 
• PE recurrence  0.07
 Central5 (100.0%)2 (50.0%) 
Sub segmental0 (0.0%)2 (50.0%) 
Primary Safety Outcomes
Safety outcome  0.65
 No bleeding59 (73.8%)55 (78.6%) 
 Minor bleeding12 (15.0%)7 (10.0%) 
 Major bleeding9 (11.2%)8 (11.4%)